Investors event calendar
View recent presentations and learn more about upcoming events.
July 18, 2024
Second quarter 2024 results
Basel, Switzerland
Environmental, Social and Governance (ESG)
Novartis aims to hold itself to the highest standards of sustainability and ethical business practices. We take bold steps to increase access to medicines, tackle complex global health challenges, and do our part as a responsible corporate citizen.
ESG updates: April 2024 (PDF 1.0 MB) | February 2024 (PDF 0.6 MB) | November 2023 (PDF 1.0 MB) | August 2023 (PDF 0.3 MB)
Latest updates: Impact & Health Equity (PDF 9.9 MB) | Novartis Enterprise Risk Management (PDF 0.2 MB) | Materiality Assessment
We have created a set of environmental, social and governance indices to signpost where our key disclosures can be found across our publications and channels. Novartis aims to report comprehensively and transparently for all stakeholders concerned with ESG topics.
Reporting and transparency hub
Read our regulatory filings; policies, codes and guidelines that govern our activities; and environmental, social and governance (ESG) disclosures.
Media releases
Novartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CML
Novartis Phase III data confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria
Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio
Pulse updates
Novartis receives FDA Breakthrough Therapy designation for Scemblix® in 1L CML
Novartis implements manufacturing adjustments for ribociclib to ensure alignment with latest regulatory standards in eBC by end of Q2
Novartis confirms plans to file for Pluvicto® pre-taxane label expansion in H2 2024 based on latest data from Phase III PSMAfore study
Novartis AG
Lichtstrasse 35
CH-4056 Basel, Switzerland